Tamoxifen in Malignant Melanoma

Richard A. Nesbit; Robert L. Woods; Martin H.N. Tattersall; Richard M. Fox; John F. Forbes; Ian R. Mackay; M. Goodyear

doi:10.1056/NEJM197911293012218

Tamoxifen in Malignant Melanoma

Richard A. Nesbit, Robert L. Woods, Martin H.N. Tattersall, Richard M. Fox, John F. Forbes, Ian R. Mackay, M. Goodyear

Producción científica: Contribución a una revista › Carta › revisión exhaustiva

46 Citas (Scopus)

Resumen

To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.¹ We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

Idioma original	English
Páginas (desde-hasta)	1241-1242
Número de páginas	2
Publicación	New England Journal of Medicine
Volumen	301
N.º	22
DOI	https://doi.org/10.1056/NEJM197911293012218
Estado	Published - nov. 29 1979
Publicado de forma externa	Sí

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Case Reports
Letter

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1056/NEJM197911293012218

Otros archivos y enlaces

Citar esto

@article{ba47060e5ce0418ea7b69cfde64d5e6e,

title = "Tamoxifen in Malignant Melanoma",

abstract = "To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.",

author = "Nesbit, {Richard A.} and Woods, {Robert L.} and Tattersall, {Martin H.N.} and Fox, {Richard M.} and Forbes, {John F.} and Mackay, {Ian R.} and M. Goodyear",

year = "1979",

month = nov,

day = "29",

doi = "10.1056/NEJM197911293012218",

language = "English",

volume = "301",

pages = "1241--1242",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "22",

}

TY - JOUR

T1 - Tamoxifen in Malignant Melanoma

AU - Nesbit, Richard A.

AU - Woods, Robert L.

AU - Tattersall, Martin H.N.

AU - Fox, Richard M.

AU - Forbes, John F.

AU - Mackay, Ian R.

AU - Goodyear, M.

PY - 1979/11/29

Y1 - 1979/11/29

N2 - To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

AB - To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

UR - http://www.scopus.com/inward/record.url?scp=0018602550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018602550&partnerID=8YFLogxK

U2 - 10.1056/NEJM197911293012218

DO - 10.1056/NEJM197911293012218

M3 - Letter

C2 - 503125

AN - SCOPUS:0018602550

SN - 0028-4793

VL - 301

SP - 1241

EP - 1242

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 22

ER -

Tamoxifen in Malignant Melanoma

Resumen

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto